Alnylam Pharmaceuticals Inc (ALNY)
152.33
+2.02
(+1.34%)
USD |
NASDAQ |
May 03, 16:00
152.43
+0.10
(+0.07%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value: 17.92B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 17.92B |
| May 02, 2024 | 17.66B |
| May 01, 2024 | 17.62B |
| April 30, 2024 | 16.86B |
| April 29, 2024 | 17.29B |
| April 26, 2024 | 16.78B |
| April 25, 2024 | 16.82B |
| April 24, 2024 | 16.84B |
| April 23, 2024 | 17.12B |
| April 22, 2024 | 17.09B |
| April 19, 2024 | 16.91B |
| April 18, 2024 | 17.01B |
| April 17, 2024 | 17.03B |
| April 16, 2024 | 17.21B |
| April 15, 2024 | 17.33B |
| April 12, 2024 | 17.43B |
| April 11, 2024 | 17.88B |
| April 10, 2024 | 17.92B |
| April 09, 2024 | 18.37B |
| April 08, 2024 | 18.38B |
| April 05, 2024 | 18.07B |
| April 04, 2024 | 17.81B |
| April 03, 2024 | 17.72B |
| April 02, 2024 | 17.75B |
| April 01, 2024 | 18.04B |
| Date | Value |
|---|---|
| March 31, 2024 | 17.55B |
| March 28, 2024 | 17.48B |
| March 27, 2024 | 18.10B |
| March 26, 2024 | 17.80B |
| March 25, 2024 | 17.81B |
| March 22, 2024 | 17.11B |
| March 21, 2024 | 17.05B |
| March 20, 2024 | 17.22B |
| March 19, 2024 | 17.24B |
| March 18, 2024 | 17.15B |
| March 15, 2024 | 17.38B |
| March 14, 2024 | 17.29B |
| March 13, 2024 | 17.27B |
| March 12, 2024 | 17.05B |
| March 11, 2024 | 17.36B |
| March 08, 2024 | 17.45B |
| March 07, 2024 | 17.46B |
| March 06, 2024 | 17.43B |
| March 05, 2024 | 17.43B |
| March 04, 2024 | 17.48B |
| March 01, 2024 | 17.80B |
| February 29, 2024 | 17.61B |
| February 28, 2024 | 18.13B |
| February 27, 2024 | 18.61B |
| February 26, 2024 | 18.56B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.802B
Minimum
May 20 2019
28.44B
Maximum
Dec 21 2022
17.14B
Average
17.14B
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 5.073B |
| Pfizer Inc | 215.90B |
| Blueprint Medicines Corp | 6.092B |
| BridgeBio Pharma Inc | 6.417B |
| Madrigal Pharmaceuticals Inc | 4.055B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.94M |
| Revenue (Quarterly) | 494.33M |
| Total Expenses (Quarterly) | 537.77M |
| EPS Diluted (Quarterly) | -0.52 |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -13.34% |
| Earnings Yield | -1.76% |
| Normalized Earnings Yield | -1.405 |